Evidence map›Paper›PMID 40353916›Full record

ReviewMedical oncology (Northwood, London, England)2025

Advanced functionalized chitosan nanocomposites for hyperthermia-based cancer therapy.

Mohamed J Saadh, Jayanti Makasana, Suhas Ballal, Roopashree R, Lokesh Verma, Piyus Kumar Pathak, Haider Radhi Saud, Suman Saini, Pushpa Negi Bhakuni, Fadhil Faez Sead

Abstract readReview
PubMed Publisher
In one paragraph

Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mohamed J SaadhFaculty of Pharmacy, Middle East University, Amman, 11831, Jordan. msaadh@meu.edu.jo.
Jayanti MakasanaDepartment of Chemistry, Faculty of Science, Marwadi University Research Center, Marwadi University, Rajkot, Gujarat, 360003, India.
Suhas BallalDepartment of Chemistry and Biochemistry, School of Sciences, JAIN (Deemed to be University), Bangalore, Karnataka, India.
Roopashree RDepartment of Chemistry and Biochemistry, School of Sciences, JAIN (Deemed to be University), Bangalore, Karnataka, India.
Lokesh VermaCentre for Research Impact & Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura, Punjab, 140401, India.
Piyus Kumar PathakDepartment of Applied Sciences-Chemistry, NIMS Institute of Engineering & Technology, NIMS University Rajasthan, Jaipur, India.
Haider Radhi SaudCollege of Health and Medical Technology, National University of Science and Technology, Dhi Qar, 64001, Iraq.
Suman SainiDepartment of Allied Science, Graphic Era Hill University, Bhimtal, India.
Pushpa Negi BhakuniGraphic Era Deemed to be University, Dehradun, Uttarakhand, India.
Fadhil Faez SeadDepartment of Dentistry, College of Dentistry, The Islamic University, Najaf, Iraq.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chitosan-based nanocomposites have emerged as promising platforms in hyperthermia-mediated cancer therapy due to their unique physicochemical properties, biocompatibility, and functional versatility. This review highlights recent advances in the design and application of chitosan-functionalized nanoparticles (NPs), focusing on their role in enhancing targeted hyperthermic treatment. The integration of chitosan with various nanomaterials-including magnetic nanoparticles, carbon-based structures such as graphene and carbon nanotubes, and gold nanoparticles-offers distinct advantages in thermal conversion efficiency, tumor specificity, and drug delivery potential. Magnetic nanoparticles allow precise thermal ablation of cancer cells under an external magnetic field, while carbon-based materials provide superior thermal conductivity for efficient heat generation. Gold nanoparticles, when conjugated with chitosan, improve biocompatibility and enable surface modification for targeted therapy. Despite promising preclinical outcomes, challenges remain in terms of toxicity, long-term stability, regulatory approval, and scalable synthesis. This review critically examines these aspects and outlines future directions for optimizing chitosan-based nanocomposites toward clinical translation and commercial viability in cancer hyperthermia therapy.

Indexed as

ChitosanHyperthermia, InducedNanocompositesNeoplasmsAnimalsDrug Delivery SystemsHumansChitosanCancer therapyChitosanHyperthermiaNanocompositesNanoparticles

Identifiers

PMID40353916

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.